eli lilly small molecule glp 1 Beyond the Needle: Lilly's Orforglipron and the GLP-1 Revolution Lilly's New Oral GLP-1 Orforglipron

Correct supplies support safe handling during repeated preparation activities

The new prescription capability means patients do not need to navigate a prior authorization transfer from their previous branded provider

Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy

FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available

Mehta, L